Stem Cell

Stem Cells by Blue Horizon

microscope icon

Our research

Our research has been published in “Experimental and therapeutic medicine” cited at PubMed Central, US National Library of Medicine, National Institutes of Health; “CellR4”, the official journal of The Cure Alliance...

injection icon

Our Stem Cell

Our stem cell products evaluated in clinical studies are collected in accordance with Good Tissue Practice to ensure safety. The studies have been conducted following approval by an Investigational Research Board...

result icon

Our Results

Our results show our cellular products are safe and effective in the improvement of symptoms related to chronic inflammation, spinal cord injury, stroke, musculoskeletal disorders and other medical conditions.

dna icon

Cultured Wharton’s Jelly And Umbilical Cord Blood

Cultured Wharton's Jelly, along with stem cell therapies derived from umbilical cord blood and adipose tissue, are showing promise in clinical trials for treating various medical conditions, such as osteoarthritis, spinal cord injury, and heart disease.

brain icon

acute ischemic stroke

The Food and Drug Administration (FDA) has given us approval to proceed with our Investigational New Drug (IND) application allowing for the initiation of a clinical study of an FDA-approved cell therapy (HCP, cord blood)...

What are Stem Cells

Stem cells are essentially “blank slate” cells that possess the remarkable potential to differentiate to any one of the billions of cells that form the diverse tissues of the human body. Stem cells have the power to divide virtually without limits and convert or develop into specialized cells that can replace injured or damaged tissue. Additionally, stem cells are known to secrete cytokines (small secreted proteins released by cells) that have immunomodulatory effects that have been demonstrated to exert a therapeutic effect. Stem cells have been shown to migrate to sites of injury and inflammation where they are believed to support the survival of damaged cell and inhibit the immune responses. Tissue-specific stem cells (“adult” or “somatic” stem cells), are already specialized and can produce different cell types for the specific tissue or organ in which they reside. Stem cell research is the most exciting option in the field of regenerative medicine being tested for efficacy in treating a variety of health issues where the body’s own response to traditional treatment isn’t sufficient to restore health and optimum function. Stem cell application in clinical trials shows promising results in therapy of neurological, musculoskeletal, cardiovascular and metabolic diseases. Stem cell therapies and regenerative medicine are becoming the preferred substitutes for many surgical, pharmacological, and rehabilitative medical services.

Revolutionary Stem Cell Therapy

Explore the power of stem cells in treating various medical conditions.

Neurological Marvels

  • Defying Alzheimer's
  • Parkinson’s Breakthrough
  • Huntington's Hope
  • Spinal Cord Regeneration
  • Battling ALS
  • Stroke Recovery
  • Multiple Sclerosis Relief

Cardiovascular Miracles

  • Healing Hearts
  • Coronary Revival
  • Unleashing Regeneration
  • Defying Congenital Defects
  • Myocardial Rejuvenation
  • Vascular Restoration
  • Cardiomyopathy Triumph
  • Reversing Atherosclerosis

Musculoskeletal Wonders

  • Cartilage Rebirth
  • Bone Tissue Regrowth
  • Osteogenesis Imperfecta Remedy
  • Osteoarthritis Solutions
  • Rheumatoid Arthritis Breakthrough

Kidney Regeneration

  • Glomerulonephritis Triumph
  • Renal Disease Reversal
  • Acute Kidney Recovery
  • Renal Artery Restoration
  • Fighting Renal Fibrosis

Lung Restoration

  • Rescuing Lungs
  • Asthma Relief
  • Bronchopulmonary Transformation
  • Defying COPD

Liver Regeneration

  • Reviving Liver Function
  • Cirrhosis Reversal

Bowel Revolution

  • Conquering Crohn's Disease

Hematological Breakthroughs

  • Defeating Leukemia
  • Myelodysplastic Syndrome Solution
  • Overcoming Aplastic Anemia
  • Thalassemia Triumph

Metabolic Transformation

  • Diabetes Remission

BHI Stem Cell Sources

Allogenic (genetically similar, but not identical) Stem Cells

Human Umbilical cord blood (hUCB)

  • Rich source of hematopoietic stem and progenitor cells as well as non-hematopoietic stem cells such as: endothelial cells, mesenchymal stem cells (MSCs) and unrestricted somatic stem cells (USSC).
  • Cells from UCB can be used directly after isolation without expansion.
  • The human leukocyte antigen type (HLA) does not need a closely-matched-donor for non-hematopoietic purposes (growth factor production, immune modulation), because these cells are less likely to induce See more...

Autologous (obtained from the same individual) Stem Cells

Adipose Tissue derived stem cell

  • Adipose tissue can be easily obtained: almost without pain under local anesthesia; without risk of thrombosis or introduction of infection into the bone marrow resulting in sepsis or osteomyelitis.
  • Stromal vascular fraction of adipose tissue contains mesenchymal stem cells that have the capacity to differentiate into cartilage, bone, muscle, and adipose tissue. Mesenchymal stem cells have been proposed as an optimal regenerative cellular therapeutic for musculoskeletal conditions like osteoarthritis and rheumatoid arthritis.

BHI Stem Cell Quality And Research

BHI Stem Cells has taken every precaution to ensure the safety and viability of administered stem cells. BHI stem cells are tested for sterility, infectious diseases and have high cell count and viability. Every unit of Human Umbilical Cord Blood Mononuclear Cells and Human Umbilical Cord Mesenchymal Stem Cells has the Cell Quality Certificate with the following information: Virus Tests (Hepatitis B virus, Hepatitis C virus, Human Immunodeficiency virus and Treponema pallidum), Microbiological Tests (Bacteria, Fungus, Mycoplasma, Endotoxin), the cell count and viability.


Cell Quality Certificate

Cell Quality Certificate for Human Umbilical Cord Blood Mononuclear Cells

Issued Aug 2022

View Certificate

Published Research

Safety Study of Intravenously Administered Human Cord Blood Stem Cells in the Treatment of Symptoms Related to Chronic Inflammation

View Research

Published Research

A Clinical Trial Report of Autologous Bone Marrow Derived Mesenchymal Stem Cell Transplantation in Patients with Spinal Cord Injury

View Research

Published Research

Allogeneic umbilical cord blood mononuclear cell therapy for spinal cord injury

View Research

Published Research

A Retrospective Study of Stromal Vascular Fraction Cell Therapy for Osteoarthritis

View Research

Published Research

Case Series: Dendritic Cell- Cytokine Induced Killer Cell Therapy in Subjects with Chronic Lymphocytic Leukemia and Peritoneal Cancer

View Research

Published Research

Evaluation of Immune response to Human Cord Blood Stem Cells in the Treatment of Symptoms Related to Chronic Inflammation

View Research

Published Research

This original clinical study article describes the use and safety of umbilical cord wharton’s jelly derived-mesenchymal stem cell therapy for a range of indications.

View Research

BHI Stem Cells Regulatory Compliance

two doctors talking in a lab

Hundreds of allogeneic stem cell therapies are underway in humans for a wide-range of medical conditions. However, these studies are not always following regulatory compliances; accordingly they have not been proven to be safe. BHI Stem Cells has unique advantages over its competitors. We are in regulatory compliance in each country we conduct clinical trials to ensure the lab and clinical procedures are lawfully approved by their federal agencies. Based on our nonclinical and pilot clinical study results, showing the safety of our hUCB product, we are planning to start IND clinical trials. FDA endorsed our Investigator-led IND (Investigational New Drug) application to allow for initiation of a clinical study of an FDA-approved cell therapy (HCP, cord blood) for treatment of acute ischemic stroke. This prospective, open-label, single-center, exploratory clinical study is designed to characterize the safety and efficacy profile of HCP, cord blood, when administered by intravenous infusion and intrathecal injection, in subjects who have sustained an acute ischemic stroke. Intravenous infusion of HCP, cord blood, in conjunction with mannitol, will be used in instances where a subject is unable to tolerate intrathecal administration.

In specific markets around the world, there is both the unmet need and the financial opportunity to establish medical facilities that provide the same quality as that found in the best facilities in the United States. BHI Stem Cells believes it is uniquely positioned to become a leader in providing the highest quality cellular therapies through centers it intends to locate throughout the world. BHI Stem Cells has recruited top medical professionals and scientific advisors, and regulatory specialists to help determine the best possible procedures to offer, to provide the appropriate protocols to monitor safety and efficacy, to collect and analyze outcome data for potential submission to the FDA and EMA, and to innovate patent procedures, devices, and therapies for future commercialization.

two doctors talking in a lab

Stem Cells: The Next Frontier